Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
Blood Adv
.
2022 Dec 13;6(23):5951-5955.
doi: 10.1182/bloodadvances.2022008932.
Authors
Juan G Ripoll
1
,
Ellen K Gorman
1
,
Justin E Juskewitch
2
,
Raymund R Razonable
3
,
Ravindra Ganesh
4
,
Ryan T Hurt
4
,
Elitza S Theel
2
,
James R Stubbs
2
,
Jeffrey L Winters
2
,
Sameer A Parikh
5
,
Neil E Kay
5
6
,
Michael J Joyner
1
7
,
Jonathon W Senefeld
1
7
Affiliations
1
Department of Anesthesiology and Perioperative Medicine.
2
Department of Laboratory Medicine and Pathology.
3
Division of Public Health, Infectious Diseases, and Occupational Medicine.
4
Division of General Internal Medicine.
5
Division of Hematology.
6
Department of Immunology.
7
Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN.
PMID:
36156121
PMCID:
PMC9519378
DOI:
10.1182/bloodadvances.2022008932
No abstract available
MeSH terms
COVID-19 Serotherapy
COVID-19* / therapy
Humans
Immunization, Passive
Immunosuppression Therapy
Vaccines*
Substances
Vaccines
Grants and funding
P30 CA015083/CA/NCI NIH HHS/United States
R35 HL139854/HL/NHLBI NIH HHS/United States